Implantable drug delivery devices for localized drug delivery

US11173291B2 · kind B2 · utility

Assignees

• The Regents of the University of California · US
• Alessa Therapeutics, Inc. · US

Inventors

• Maithili Rairkar · San Francisco, US
• Pujan Desai · Oakland, US
• Carlos Schuler · Cupertino, US
• Maxime Daud · San Francisco, US
• Maxime D. Rappaport · San Francisco, US
• Pamela Munster · Hillsborough, US
• John Maroney · San Francisco, US
• Margaret McLaughlin · San Francisco, US
• Tobias H. Casab · San Francisco, US
• Keith Hall · San Francisco, US
• Scott Thomas · Oakland, US

Key dates

• Filing date: Mar 20, 2020
• Grant date: Nov 16, 2021
• Expiry date: Mar 20, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61M2210/166
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.